Super Group (SGHC) Limited reports Q1 2026 results today with the stock running hot — up nearly 29% over the past month to $13.18 — while the options market and short data tell a markedly more relaxed story than the price action might suggest.
Options positioning is marginally more defensive than usual, but not by much. The put/call ratio has edged up to 0.04, about 1.3 standard deviations above its 20-day average of 0.033 — a very slight uptick in hedging demand, but one that comes from an extremely low base. With the PCR still near historic lows relative to its 52-week range (high of 2.05, low of zero), call activity continues to dominate. That reflects the same bullish momentum that has been driving the stock for weeks.
Short positioning adds little friction to that story. Short interest is running at 5.3% of the free float — meaningful but not elevated — and borrow availability is ample at around 118% of current short interest, meaning there is plenty of supply in the lending pool for anyone looking to add exposure. Cost to borrow has crept up roughly 23% over the past week to 0.57% APR, though in absolute terms that remains very cheap. The short score of 58 has ticked higher recently, primarily reflecting tighter availability in a specific session (utilisation briefly hit its 52-week peak on May 7 before easing back). That one-day spike looks like noise rather than a structural shift; the broader borrow market remains uncrowded.
The analyst debate is more measured than the share price rally implies. Consensus sits firmly constructive, with BTIG reiterating its Buy at $16 in mid-April — above the current price but well below where the stock was priced at the start of the year. Bulls point to Betway and Spin segment momentum, African market expansion, and a disciplined operational track record. Bears flag the bear case more directly: estimate cuts that flowed through to lower 2025 and 2026 revenue and EBITDA forecasts, plus a valuation that has re-rated sharply — the P/E has expanded roughly 3.4 turns over the past month alone to about 16.4x, and price-to-book has risen by a full turn to 5.1x. The mean analyst target of $17.50 implies about 33% upside from current levels, though the consensus data is dated to mid-March and may not yet reflect the full extent of the recent rally.
One note on insider activity: the CEO, CFO, and two other executives all sold shares on April 8 at $10.71 — a price roughly 23% below where the stock trades today. Those sales followed stock awards made the week prior and carry low trade-significance scores, suggesting routine post-vesting disposals rather than a directional view. The more notable institutional development is Invesco adding over 3.1 million shares in Q1, bringing its stake to just over 0.8% — a small but constructive move from a major passive and active manager.
Today's print is therefore a test of whether Q1 revenue and EBITDA can justify a valuation that has re-rated aggressively ahead of the numbers.
See the live data behind this article on ORTEX.
Open SGHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
